Common sense is dead, and careers are made from useless research.
open.substack.com
I don't read Prasad often and have disagreed with him on specific issues in the past. He is pretty opposed to lung CA screening, and usually I am not.
He is well aware that controversial positions carry more purchase regarding building a personal brand than conventional ones. It's a pretty seductive position to many "Kennedy anyone" to position yourself in opposition to the medical establishment.
On this particular paper, I agree with him. However, I don't agree with the narrative that this type of research is why "we" are collectively lamenting low impact research in our field. I suspect there are anecdotal cases that are very bothersome to us. Academics building careers and getting promotions based on non-actionable disparity research, when doing real science is just very, very tough and other docs are seemingly getting passed by.
But, nearly all research is low impact. I would argue that most basic science research is so esoteric that only a sliver of it becomes incorporated into applied work. This doesn't mean that basic science research is not valuable or critical. You need lots of low impact work to support the rare high impact work. Often basic science work will demonstrate impact decades after publication, if only in directing the work of others.
What we are lamenting is the lack of clinically "high impact" therapies or narratives emerging from all of our research effort.
This is not because of docs doing DEI stuff. This is because our field is unlikely to be the source of such a therapy or story...period. Cancer is overwhelmingly a nuanced, high variance, biologically driven phenomenon, and we are in the business of refining a physical tool. It's just not that fruitful anymore. We collectively jumped on XRT as an immune modulator based on case reports and low variance animal studies. We have invested enormous amounts in pursuing a very high cost intervention that deposits energy slightly differently (and much less predictably) than photons. Neither of these have given us anything resembling the types of KM curves we routinely see with new targeted systemic therapy nowadays.
Lets not create a false bogeyman.
Risk stratification, reduced fractionation, reduced volumes, personalized avoidance of XRT altogether and DEI is what we've got.
How many iterations of systemic therapy have our medonc colleagues seen in the past 8 years regarding triple negative breast cancer? Oh yeah,...and it matters.